Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.95 USD | -2.96% | -1.67% | -28.74% |
Jun. 05 | Goldman Sachs Downgrades Relmada Therapeutics to Sell From Neutral With $2 Price Target | MT |
May. 08 | Transcript : Relmada Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024 |
- Stock Market
- Equities
- RLMD Stock
- News Relmada Therapeutics, Inc.
- Press Releases